

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of

Complete if Known

| | |
|---------------------------|------------|
| Application Number | 10/604,591 |
|---------------------------|------------|

| | |
|--------------------|------------|
| Filing Date | 08/01/2003 |
|--------------------|------------|

| | |
|----------------------|-----------------------|
| First Named Inventor | Thomas Freeman et al. |
|----------------------|-----------------------|

| | |
|----------------|------------|
| Group Art Unit | Unassigned |
|----------------|------------|

| | |
|---------------|------------|
| Examiner Name | Unassigned |
|---------------|------------|

| | |
|------------------------|---------|
| Attorney Docket Number | 1372.50 |
|------------------------|---------|

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**


Date
Considered

5117105

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Information Freedom Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------------|
| Substitute for form 1449B/PTO | | Compleat if Kn wn | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/604,591 |
| | | Filing Date | 08/01/2003 |
| | | First Named Inventor | Thomas Freeman et al. |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet 2 | of | Attorney Docket Number | 1372.50 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AS | 4 | LANGEVIN ET AL.; Rabies Virus Glycoprotein (RVG) is a Trimeric Ligand for the N -Terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor; Journal of Biological; | |
| | 5 | THOMAS FREEMAN; The Prospects for Vaccination Against Herpes Viruses; Power Point Presentation; 2001 | |
| | 6 | Herpesvirus Replication; http://darwin.bio.uci.edu/~faculty/wager/movietext.html ; 9/5/2001 | |
| | 7 | EISENBERG, Ph.D.; University of Pennsylvania School of Veterinary Medicine; 9/5/2001 | |
| | 8 | FERSON; Varicella Vaccine in Post-Exposure Prophylaxis; http://health.gov.au/pubhlth/cdi2501/cdi2501e.htm ; 9/5/2001 | |
| | 9 | KUTER ET AL.; Efficacy of OKA/Merck Varicella Vaccine After Concomitant Administration with M-M-R II; 9/5/2001 | |
| | 10 | Varicella Virus Vaccine Live (Oka/Merch); www.geocities.com/mom2q/CPVaccineInsert.htm ; 9/5/2001 | |
| | 11 | Facts About Shingles (Varicella-Zoster Virus); www.niaid.nih.gov/factsheetsFS.htm ; 9/5/2001 | |
| | 12 | EHRMAN; A Potential Shingles Vaccine; www.nih.gov/news/WordonHealth/oct2000/story03.htm ; 10/2000 | |
| | 13 | History of Rabies; http://justice.loyola.edu/~klc/BL472/Rabies/rabies~1.htm | |
| | 14 | MASCOLA; Herpes Simplex Virus Vaccines - WHY Don't Antibodies Protect?; http://jama.ama.assn.org/issues/v282n4/full/jed90053.html ; Vol 282, No. 4; 7/28/1999 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 5/17/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type and sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | |
| | | Application Number | 10/604,591 | |
| | | Filing Date | 08/01/2003 | |
| | | First Named Inventor | Thomas Freeman et al. | |
| | | Group Art Unit | Unassigned | |
| | | Examiner Name | Unassigned | |
| Sheet | 3 | of | Attorney Docket Number | 1372.50 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| A ↓ | 15 | COREY ET AL.; Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection; American Medical Association; 7/28/1999; Vol. 282, No. 4, pg.331-340 | |
| | 16 | The Big Picture Book of Viruses: Herpesviridae; www.virology.net/Big_Virology/BVDNAherpes.html; 9/5/2001 | |
| | 17 | Virus Antigens; www.virotest.com/products3_e.htm; 9/5/2001 | |
| | 18 | IMOGAM Rabies Pasteurized [Rabies Immune Globulin, Pasteurized (Human)]; | |
| | 19 | SHERMAN, R.Ph.D.; Rabies: A History and Update on Prophylaxis Regimens in the U.S.; www.uspharmacist.com/NewLook/DisplayArticle.cfm?item_num=563; 11/26/2001 | |
| ↓ | 20 | IMOVAX Rabies [Rabies Vaccine Inactivated (DCO)] | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 5/17/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.